HAVCR2 and neoplasm: Preclinical studies have demonstrated upregulated expressions of LAG-3 or TIM-3 in immunotherapy-resistant tumors, whilst co-blockade of these checkpoint molecules augments tumor response to anti-CTLA-4 and anti-PD-1 immunotherapies [67,87].